ID   K562/MTX-2
AC   CVCL_5144
DR   CLO; CLO_0050119
DR   BioSample; SAMN03472320
DR   RCB; RCB0474
DR   Wikidata; Q54899414
RX   PubMed=2465288;
CC   Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX).
CC   Sequence variation: BCR-ABL1 gene fusion (from parent cell line).
CC   Sequence variation: Homozygous for TP53 p.Gln136fs*13 (c.406_407insC) (from parent cell line).
CC   Derived from sampling site: Pleural effusion.
ST   Source(s): RCB
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 8
ST   D16S539: 11,12
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   TH01: 6,9.3
ST   TPOX: 8,9
ST   vWA: 16
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 16
RX   PubMed=2465288; DOI=10.1111/j.1349-7006.1988.tb01549.x;
RA   Koizumi S.;
RT   "Impairment of methotrexate (MTX)-polyglutamate formation of
RT   MTX-resistant K562 cell lines.";
RL   Jpn. J. Cancer Res. 79:1230-1237(1988).